Different mechanisms are used by insulin to repress three genes that contain a homologous thymine-rich insulin response element  by Patel, Satish et al.
Di¡erent mechanisms are used by insulin to repress three genes that
contain a homologous thymine-rich insulin response element
Satish Patel, Christopher Lipina, Calum Sutherland
Department of Pharmacology and Neurosciences, University of Dundee, Ninewells Medical School and Hospital, Dundee DD1 9SY, UK
Received 3 February 2003; revised 19 May 2003; accepted 30 June 2003
First published online 17 July 2003
Edited by Robert Barouki
Abstract Insulin rapidly and completely inhibits expression of
the hepatic insulin-like growth factor binding protein-1 (IGFBP-
1), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-
6-phosphatase (G6Pase) genes. This inhibition is mediated
through a phosphatidyl inositol 3-kinase-dependent regulation
of a DNA element, termed the thymine-rich insulin response
element, found within the promoters of each of these genes.
This has led to the conclusion that these three promoters are
regulated by insulin using the same molecular mechanism. How-
ever, we recently found that the regulation of the IGFBP1 but
not the PEPCK or G6Pase genes by insulin was sensitive to
rapamycin, an inhibitor of mTOR. Here, we present further
evidence that di¡erent regulatory pathways mediate the insulin
regulation of these promoters. Importantly, we identify a protein
phosphatase activity in the pathway connecting mTOR to the
IGFBP-1 promoter. These data have major implications for the
development of molecular therapeutics for the treatment of in-
sulin-resistant states such as diabetes and hypertension.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Insulin is secreted from the pancreatic L-cells in response to
increasing glucose levels in the blood. The result is the resto-
ration of plasma glucose levels and conversion of excess glu-
cose to glycogen [1]. Insulin achieves this through the regula-
tion of protein activity, localisation and expression. Indeed,
insulin is known to regulate the expression of over 100 gene
products in multiple cell types [2]. For example, insulin com-
pletely inhibits the expression of hepatic insulin-like growth
factor binding protein-1 (IGFBP-1), phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase). IGFBP-1 binds insulin-like growth factors (for re-
view see [3]), while PEPCK and G6Pase are rate-controlling
enzymes of hepatic gluconeogenesis [4,5]. All of these genes
are over-expressed in diabetes [6^9]. Meanwhile, PEPCK
over-expression in animals promotes hyperglycemia, impaired
glucose tolerance and insulin resistance [10^12], and increased
G6Pase expression in mice produces a metabolic pro¢le sim-
ilar to Type 2 diabetes [13]. Interestingly, these three gene
promoters contain a homologous DNA element, termed the
thymine-rich insulin response element (TIRE), through which
insulin mediates at least part of its inhibitory e¡ect [5]. The
presence of this element in these promoters initially suggested
that insulin employs a common mechanism to repress each.
This hypothesis was strengthened when several groups ob-
served that insulin requires phosphatidyl inositol 3-kinase
(PI 3-kinase) activity for regulation of PEPCK [14,15],
G6Pase [16] and IGFBP-1 [17] expression. However, the in-
sulin regulation of the IGFBP-1 but not G6Pase or PEPCK
gene promoters is sensitive to rapamycin [14,17,18]. Therefore,
the activity of mTOR is required for regulation of IGFBP-1
but not PEPCK or G6Pase by insulin. It is not yet understood
how mTOR regulates the IGFBP-1 promoter but studies in
yeast have implicated Tor (yeast mTOR) in the regulation of a
protein phosphatase [19,20]. Therefore, we investigated the
e¡ect of okadaic acid, a diarrhoetic shell¢sh toxin that selec-
tively inhibits protein phosphatases 1 (PP1) and 2A (PP2A),
on the regulation of IGFBP-1 expression. This agent is known
to repress PEPCK gene expression [21] ; therefore we also
examined its e¡ect on the expression of a third TIRE-contain-
ing gene, G6Pase. The data presented herein provide further
evidence that insulin regulates IGFBP-1 gene expression by a
mechanism distinct from that used to regulate G6Pase and
PEPCK, and implicates a protein phosphatase in the pathway
from mTOR to the IGFBP-1 promoter.
2. Materials and methods
Radioisotopes were obtained from Amersham, Bucks, UK
([Q32P]ATP) and ICN, Thame, Oxfordshire, UK ([K32P]UTP). Insulin
was purchased from Novo Nordisk (Crawley, West Sussex, UK),
okadaic acid from Calbiochem (Nottingham, UK), and the RNase
Protection Assay kit II from AMS Biotech/Ambion (Austin, TX,
USA). All other chemicals were of the highest grade available.
2.1. Cell culture
The rat hepatoma cell line H4IIE was maintained in Dulbecco’s
Modi¢ed Eagle’s medium (DMEM) containing 1000 mg/l glucose,
5% (v/v) foetal calf serum, as described previously [22]. Cells were
incubated with hormones, at 37‡C, for the times and at the concen-
trations indicated in the ¢gure legends.
2.2. RNA isolation and RNase protection assay
H4IIE cells were serum-starved overnight and treated with hor-
mone/inhibitor for the times and at the concentrations indicated. To-
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tal cellular RNA was isolated using TriReagent1 (Sigma) following
the manufacturer’s instructions. An RNase protection assay (RPA)
was performed to determine the relative amounts of IGFBP-1,
G6Pase and cyclophilin mRNA in each sample [22,23]. Band intensity
was quanti¢ed on a phosphorimager (Fuji) and data calculated as a
ratio of IGFBP-1 or G6Pase to cyclophilin mRNA.
2.3. Preparation of cell extract for kinase assays and Western blot
H4IIE cells were incubated in serum-free medium with hormones
and inhibitors for the times and at the concentrations indicated. Cells
were then scraped into ice-cold lysis bu¡er (25 mM Tris^HCl, pH 7.4,
50 mM NaF, 100 mM NaCl, 1 mM sodium vanadate, 5 mM EGTA,
1 mM EDTA, 1% (v/v) Triton X-100, 10 mM sodium pyrophosphate,
1 mM benzamidine, 0.1 mM PMSF, 0.27 M sucrose, 2 WM micro-
cystin and 0.1% (v/v) 2-mercaptoethanol). Cell debris was removed by
centrifugation at 13 000Ug and the protein concentration determined.
Protein kinases were immunoprecipitated and assayed as described
previously [18].
3. Results and discussion
3.1. Insulin requires the activity of a phosphatase to repress
IGFBP-1
Okadaic acid is a potent inhibitor of PP1 and PP2A [24,25].
Previous studies suggested that okadaic acid could mimic the
e¡ect of insulin on PEPCK gene expression, implicating pro-
tein phosphorylation as a major mechanism by which insulin
regulated this gene promoter [21]. In contrast, treatment of
H4IIE cells with okadaic acid alone, even at concentrations
up to 1 WM, has little e¡ect on IGFBP-1 mRNA levels, but
the presence of this agent dramatically reduces insulin repres-
sion of IGFBP-1 (Fig. 1A). Okadaic acid antagonises the in-
sulin regulation of both basal and dexamethasone-induced
IGFBP-1 expression (Fig. 1A), although the e¡ect of okadaic
acid is not as complete when the gene is induced. In addition,
within the same experiment, the presence of 1 WM okadaic
acid reduces G6Pase gene expression, similar to its reported
e¡ect on PEPCK expression [21]. However, the repression is
not as complete as that observed in the presence of insulin
(Fig. 1B). Meanwhile, lower concentrations (0.1 WM) of oka-
daic acid have no signi¢cant e¡ect on insulin regulation of
IGFBP-1 or G6Pase expression (data not shown). Similarly,
insulin regulation of IGFBP-1 gene expression is not signi¢-
cantly reduced by the PP1 inhibitor tautomycin (data not
shown). Unfortunately, a third phosphatase inhibitor, Caly-
culin-A, is extremely toxic to the H4IIE cells at concentrations
required to inhibit PP2A; therefore we were not able to make
use of this inhibitor.
These data con¢rm the importance of phosphorylation in
the regulation of both promoters and although they suggest
the involvement of a phosphatase in insulin regulation of the
IGFBP-1 promoter, they do not reveal the identity of the
phosphatase involved. We have previously shown that
mTOR is required for the regulation of IGFBP-1 gene expres-
sion by insulin [18]. Interestingly, an inhibitor of mTOR only
partially reduces insulin regulation of IGFBP-1 expression,
reminiscent of the e¡ect of okadaic acid. In mammals, rela-
tively little is known about the role of mTOR as a direct
transcriptional regulator. However, in yeast, Tor is a regulator
of several transcription factors [26,27]. Genetic evidence sug-
gests that proteins such as Tap42p, Ure2 and Bmh2p are
important in the Tor regulation of speci¢c transcription fac-
tors [20,27]. Tap42p is a protein that binds and inhibits the
protein phosphatase SIT4. Upon Tor inactivation by rapamy-
cin treatment or starvation, SIT4 is released from Tap42,
leading to the dephosphorylation and nuclear translocation
of Gln3 and subsequent activation of target genes [19,20,28].
Therefore, in yeast Tor appears to negatively regulate a phos-
phatase. Human K4 protein is the closest mammalian homo-
logue of Tap42 [29,30]. K4 can bind to the protein phospha-
tases PP2A, PP4 and PP6; however, whether the formation of
this complex is rapamycin-sensitive remains controversial.
Meanwhile, mTOR has also been proposed to directly inhibit
PP2A, thereby providing a mechanism by which phosphory-
lation is maintained on molecules such as ribosomal protein
Fig. 1. Treatment of H4IIE cells with okadaic acid has opposing ef-
fects on insulin regulation of IGFBP-1 and G6Pase gene expression.
H4IIE cells were serum-starved overnight prior to a 3-h incubation
with dexamethasone (500 nM), cAMP (8CPT-cAMP, 0.1 mM), insu-
lin (10 nM), or okadaic acid (OA, 1 WM) as indicated. Cells were
lysed, total cellular RNA isolated, and an RPA performed to assess
A: IGFBP-1 (BP-1) and B: G6Pase mRNA levels. Results are pre-
sented as fold induction relative to control (serum-free) and are
meansPS.E.M. of two experiments performed in duplicate (upper
panels). Representative experiments (lower panels) are also shown.
*P6 0.05; **P6 0.01.
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S6 kinase (S6K1), 4EBP-1 [31,32] and PKCN [33]. In contrast,
our data suggest that insulin signalling in liver requires an
okadaic acid-sensitive phosphatase activity for regulation of
IGFBP-1 (Fig. 1A). If this is true then incubation of cells with
okadaic acid should a¡ect signalling pathways that lie be-
tween mTOR and the IGFBP-1 gene promoter.
3.2. E¡ect of okadaic acid on insulin signalling pathways in
H4IIE cells
Treatment of H4IIE cells with 1 WM okadaic acid for 30
min does not signi¢cantly alter insulin regulation of S6K, its
substrate ribosomal protein S6 (both downstream of mTOR),
or the other insulin signalling molecules, protein kinase B
(PKB), GSK3 (a target of PKB), or p42/p44 MAPK (Fig.
2). However, after a 3-h treatment, insulin activation of
S6K was signi¢cantly reduced, while activation of the p42/
44 MAPK pathway was induced (Figs. 2 and 3). This is sim-
ilar to the e¡ect of okadaic acid in adipocytes [34]. Interest-
ingly, the phosphorylation of GSK3L (Ser-9) increases with
okadaic acid treatment, in the absence of any activation of
PKB (Fig. 2). Therefore, it is likely that okadaic acid pro-
motes the phosphorylation of GSK3 through activation of
p90RSK, rather than through the activation of PKB.
p90RSK will phosphorylate and inhibit GSK3 in vitro
[35,36] and in intact cells [37].
We have previously found that agents that strongly activate
the p42/p44 MAPK pathway can reduce the sensitivity of the
IGFBP-1 (but not PEPCK or G6Pase) promoter to insulin
[23]. Therefore, it was possible that okadaic acid exerts its
e¡ect on IGFBP-1 expression through its ability to strongly
Fig. 2. E¡ect of okadaic acid on insulin signalling in H4IIE cells. H4IIE cells were serum-starved overnight and incubated with insulin (10 nM)
and/or okadaic acid (OA, 1 WM) for the times indicated. A: Cells were lysed and the protein lysates immunoblotted with antibodies as labelled
(phospho; phosphospeci¢c to Thr-202 and Tyr-204 of p42/p44 MAPK or Ser-21/9 (GSK3K/L)). Similar results were obtained from two experi-
ments. B: Alternatively, S6K, PKB and p90rsk were immunoprecipitated and speci¢c activity assayed. Results are meansPS.E.M. of two ex-
periments performed in triplicate.
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induce p42/p44 MAPK (Figs. 2 and 3). However, treatment
with a selective inhibitor of the p42/p44 MAPK pathway does
not a¡ect the action of okadaic acid on IGFBP-1, at concen-
trations that fully block insulin and okadaic acid activation of
p42/44 MAPK (Fig. 3B). It seems more likely that okadaic
acid is exerting its e¡ects on IGFBP-1 gene expression
through the down-regulation of the mTOR pathway (Fig.
2). This is consistent with our ¢ndings that reduction of
mTOR signalling, by rapamycin or removal of amino acids,
antagonises the repression of IGFBP-1 gene transcription by
insulin [18]. Therefore, we propose that in liver cells mTOR
requires a phosphatase activity (possibly PP1 or PP2A-like) to
be present in order to activate S6K as well as repress IGFBP-
1 gene expression. The identity and direct substrate of the
phosphatase is not yet known, but is the subject of ongoing
research.
3.3. Insulin uses distinct mechanisms to regulate
TIRE-containing gene promoters
The treatment of H4IIE cells with phorbol esters [23], hy-
drogen peroxide [38], or okadaic acid (Fig. 1) blocks (at least
in part) the repression of IGFBP-1 gene expression by insulin.
Conversely, each of these agents mimics insulin regulation of
the PEPCK and G6Pase gene promoters ([21,23,38^40] and
C. Sutherland, unpublished data; Fig. 1B). Taken together
with the distinct rapamycin sensitivities of these promoters
[18], this demonstrates that despite each promoter containing
related DNA sequences, the signalling pathways that connect
PI 3-kinase activation to each are distinct. Indeed, closer ex-
amination of each promoter structure reveals major di¡eren-
ces in the context of the distinct TIREs. For example, the
PEPCK promoter contains a single TIRE, the G6Pase has
three, and the IGFBP-1 has two that lie in an inverted palin-
drome [5]. In addition, the PEPCK promoter contains a sec-
ond insulin regulatory sequence, the G6Pase promoter con-
tains an insulin accessory element, while no other insulin
regulated DNA elements have as yet been characterised for
the IGFBP-1 promoter (although our data have suggested the
existence of at least one other insulin response element in this
promoter [18]). Therefore, it is perhaps not surprising that
distinct mechanisms and probably di¡erent DNA-binding
proteins are involved in insulin regulation of these promoters.
Finally, insulin resistance underlies the development of sev-
eral common human disorders, such as Type 2 diabetes mel-
litus and hypertension [1]. These disorders are on the increase
and represent a huge drain on health care expenditure [41].
Current therapies to overcome insulin resistance are relatively
ine¡ectual, therefore a great deal of e¡ort is going into the
development of agents that can increase insulin sensitivity or
mimic the cellular actions of insulin [42]. The ¢ndings pre-
sented here demonstrate that care must be taken when design-
ing signalling mimetics, as activation of some insulin signal-
ling pathways can occur simultaneously with inhibition of
others. Ideally, a common regulator can be found that could
be a target for an insulin mimetic that would repress all
TIRE-containing promoters rather than a select few.
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